Author

M. Porteus

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Research Focus:gene regulatory network inference· 3 Research Focus:differential expression· 2 Approach:genetic perturbation / CRISPR· 2 Assay:scRNA-seq· 2 Assay:ATAC-seq· 1 Research Focus:clustering· 1

Frequent Co-Authors

G. Bao· 2 shared M. G. Roncarolo· 2 shared M. Pavel-Dinu· 2 shared A. A. Salahudeen· 1 shared A. Camus· 1 shared A. DellAglio· 1 shared A. Devaux· 1 shared A. Haydn· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

G. Bao

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Epigenetic signature and key transcriptional regulators of human antigen-specific type 1 regulatory T cells

A.-M. Cepika, L. Amaya, C. Waichler, M. Narula, M. M. Mantilla, B. C. Thomas, P. P. Chen, R. A. Freeborn, M. Pavel-Dinu, J. Nideffer, M. Porteus, R. Bacchetta, F. Mueller, W. J. Greenleaf, H. Y. Chang, M. G. Roncarolo

This study identifies the epigenetic signature and key transcription factors regulating human antigen-specific Tr1 cells, revealing their unique biology and potential for therapeutic applications.

bioRxiv · Mar 7, 2024 · PreprintImmunology

Epitope Engineered Human Haematopoietic Stem Cells are Shielded from CD123-targeted Immunotherapy

R. Marone, E. Landmann, A. Devaux, R. Lepore, D. Seyres, J. Zuin, T. Burgold, C. Engdahl, G. Capoferri, A. DellAglio, C. Larrue, F. Simonetta, J. Rositzka, M. Rhiel, G. Andrieux, , L. T. Jeker

This paper shows that epitope-engineered human hematopoietic stem cells are protected from CD123-targeted immunotherapy while maintaining functionality, offering a strategy for tumor-selective therapy.

Journal of Experimental Medicine · Sep 29, 2023Peer-reviewedBioengineering

Targeted replacement of full-length CFTR in human airway stem cells by CRISPR/Cas9 for pan-mutation correction in the endogenous locus

S. Vaidyanathan, R. Baik, L. Chen, D. T. Bravo, C. J. Suarez, S. M. Abazari, A. A. Salahudeen, A. M. Dudek, C. A. Teran, T. H. Davis, C. M. Lee, G. Bao, S. H. Randell, S. E. Artandi, J. J. Wine, , M. Porteus

This study corrects multiple CFTR mutations in human airway stem cells using CRISPR/Cas9 and AAV vectors, achieving functional restoration in differentiated epithelial cells.

bioRxiv · Feb 26, 2021Bioengineering

Gene Correction for SCID-X1 in Long-Term Hematopoietic Stem Cells

M. Pavel-Dinu, V. Wiebking, B. T. Dejene, W. Srifa, S. Mantri, C. Nicolas, C. Lee, G. Bao, E. J. Kildebeck, N. Punjya, C. Sindhu, M. A. Inlay, N. Saxena, S. S. DeRavin, H. Malech, , M. Porteus

This study corrects SCID-X1 in hematopoietic stem cells using CRISPR/Cas9, achieving high integration frequencies and low off-target effects, supporting clinical development.

bioRxiv · Aug 22, 2018Bioengineering